Category: Asean

Azerion publishes interim Q2 and H1 2023 results

Platform growth and integrations leading to increased revenue and improved margins Highlights of Q2 2023 Increased earnings driven by revenue growth and ongoing cost savings Net revenue of approximately € 122 million for Q2 2023, up from € 104 million in Q2 2022. Adjusted EBITDA of almost € 19 million,

Read more

Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates

SHANGHAI, China, Aug. 30, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2023 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTS As of 30 June

Read more

Recent News